Powder: -20°C for 3 years | In solvent: -80°C for 1 year
EPI-001 是一种选择性雄激素受体 (AR) 的抑制剂,靶向 AR 的反式激活单元 5,可抑制 AR 氨基末端结构域的反式激活,IC50值约为 6 μM。它也是一种选择性的PPARγ调节剂,对去势抵抗性前列腺癌具有活性。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 142 | 现货 | ||
2 mg | ¥ 198 | 现货 | ||
5 mg | ¥ 361 | 现货 | ||
10 mg | ¥ 662 | 现货 | ||
25 mg | ¥ 1,180 | 现货 | ||
50 mg | ¥ 1,980 | 现货 | ||
100 mg | ¥ 2,960 | 现货 | ||
200 mg | ¥ 4,280 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 392 | 现货 |
产品描述 | EPI-001 is an androgen receptor N-terminal domain antagonist with IC50 of ~6 μM and a selective PPAR-gamma modulator. |
靶点活性 | Androgen receptor:6 μM |
体外活性 | EPI-001 blocks transactivation of the AR NTD, interacts with the AF-1 region, inhibits protein-protein interactions with AR, and reduces AR interaction with androgen-response elements on target genes. In LNCaP cells, EPI-001 inhibits both androgen-dependent and androgen-independent (OCM-induced) cell proliferation. [1] In LNCaP cells, EPI-001 also acts as a PPAR-gamma modulator to result in inhibition of androgen receptor expression and activity, which inhibits prostate cancer growth. [2] |
体内活性 | In male mice bearing CRPC LNCaP s.c. xenografts, EPI-001 (50 mg/kg, i.v.) blocks the androgen-axis and inhibits androgen-dependent tumor growth by reducing proliferation and increasing apoptosis. [1] |
细胞实验 | LNCaP cells are treated with bicalutamide (BIC) or EPI-001 for 1 hr before the addition of R1881 (0.1 nM) for 4 days. LNCaP cells are treated with OCM (50%) with, or without, EPI-001 for 3 days (serum-free, androgen-free, phenol red-free conditions).(Only for Reference) |
别名 | EPI001, EPI 001 |
分子量 | 394.89 |
分子式 | C21H27ClO5 |
CAS No. | 227947-06-0 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
H2O: < 1 mg/mL (insoluble or slightly soluble)
DMSO: 70 mg/mL (177.3 mM)
Ethanol: 70 mg/mL (177.3 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO / Ethanol | 1 mM | 2.5324 mL | 12.6618 mL | 25.3235 mL | 63.3088 mL |
5 mM | 0.5065 mL | 2.5324 mL | 5.0647 mL | 12.6618 mL | |
10 mM | 0.2532 mL | 1.2662 mL | 2.5324 mL | 6.3309 mL | |
20 mM | 0.1266 mL | 0.6331 mL | 1.2662 mL | 3.1654 mL | |
50 mM | 0.0506 mL | 0.2532 mL | 0.5065 mL | 1.2662 mL | |
100 mM | 0.0253 mL | 0.1266 mL | 0.2532 mL | 0.6331 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
EPI-001 227947-06-0 Apoptosis DNA Damage/DNA Repair Endocrinology/Hormones Metabolism PPAR Androgen Receptor Androgen amino-terminal anti-tumor domain inhibit Peroxisome proliferator-activated receptors PPARγ EPI001 transactivation EPI 001 Receptor NTD Inhibitor inhibitor